However, traditional predictive biomarkers in ICI monotherapy, such as PD-L1 and tumor mutation burden (TMB), do not appear to be reliable in predicting the treatment response to ICI combination therapy [6, 7]. The gene discussed is CD274; the disease is neoplasm.